Polyrizon Ltd. Reports Positive Pre-Clinical Results for PL-14
Ticker: PLRZ · Form: 6-K · Filed: Oct 6, 2025 · CIK: 1893645
| Field | Detail |
|---|---|
| Company | Polyrizon Ltd. (PLRZ) |
| Form Type | 6-K |
| Filed Date | Oct 6, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: pre-clinical-results, medical-devices, drug-development
TL;DR
Polyrizon's PL-14 shows promise in early allergen-blocking tests, filing confirms.
AI Summary
Polyrizon Ltd. announced on October 6, 2025, positive pre-clinical results for its PL-14 product. The study demonstrated encouraging allergen-blocking efficacy, suggesting potential for the product in treating allergic conditions. These results are incorporated into the company's SEC filings.
Why It Matters
Positive pre-clinical data for PL-14 could pave the way for future clinical trials and potential market entry for a new treatment option for allergic conditions.
Risk Assessment
Risk Level: medium — Pre-clinical results are early-stage and do not guarantee success in human trials or market approval.
Key Numbers
- 001-42375 — SEC File Number (Identifies Polyrizon Ltd.'s filings with the SEC.)
Key Players & Entities
- Polyrizon Ltd. (company) — Registrant
- PL-14 (product) — Allergen-blocking efficacy study
- October 6, 2025 (date) — Press release date
- 3841 (industry_code) — Standard Industrial Classification for Surgical & Medical Instruments & Apparatus
- 001-42375 (filing_number) — SEC File Number
FAQ
What specific allergens were tested in the pre-clinical study for PL-14?
The filing does not specify the exact allergens tested in the pre-clinical study for PL-14.
When is Polyrizon Ltd. expected to initiate human clinical trials for PL-14?
The filing does not provide a timeline for the initiation of human clinical trials for PL-14.
What is the primary mechanism of action for PL-14 in blocking allergens?
The filing does not detail the specific mechanism of action for PL-14 in blocking allergens.
Are there any financial figures associated with the PL-14 pre-clinical results announcement?
The filing does not mention any specific dollar amounts or financial figures related to the PL-14 pre-clinical results.
Which SEC registration statements incorporate the press release about PL-14's pre-clinical results?
The press release is incorporated by reference into Polyrizon Ltd.'s Registration Statements on Form S-8, File No. 333-284410 and 333-288923.
Filing Stats: 256 words · 1 min read · ~1 pages · Grade level 13.8 · Accepted 2025-10-06 08:36:38
Filing Documents
- ea0260360-6k_polyrizon.htm (6-K) — 11KB
- ea026036002ex99-1_polyrizon.htm (EX-99.1) — 12KB
- 0001213900-25-096303.txt ( ) — 24KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Polyrizon Ltd. Date: October 6, 2025 By: /s/ Tomer Izraeli Name: Tomer Izraeli Title: Chief Executive Officer 2